Clinical Trials Directory

Trials / Completed

CompletedNCT02146209

Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.

Comparative Randomized, Single Dose, Three-Period Crossover Open-Label Study to Determine the Bioequivalence Of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules (Formula A)) Relative to 500 mg From Sanofi-aventis Flagyl 125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension (Formula B)) and Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablets (Formula C)) , After an Oral Administration to Healthy Adults Under Fasting Conditions

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Verisfield UK Ltd. Greek Branch · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether Terix Labs Ltd Metronidazole benzoate (400 mg Metronidazole Per Sachet Oral Granules) is bioequivalent to 500 mg Sanofi-aventis Flagyl 125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension) and to Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablets).

Detailed description

This study is a pilot study exploited for exploratory purposes to compare the absorption and disposition kinetics of three products containing metronidazole under fasting conditions. These products are: Metronidazole benzoate (formula A), Test product manufactured by ONE PHARMA, Greece. Flagyl 125 mg/5 ml (formula B), a Reference product manufactured by Unither Liquid Manufacturing, France and Flagyl™ 400 mg Tablets (formula C), a Reference product manufactured by Famar Health Care Services, Spain. The bioequivalence of a single 400 mg dose of products A and C, and a single 500 mg dose of product B will be assessed by comparing the pharmacokinetic parameters derived from the plasma concentration-time profiles for metronidazole.

Conditions

Interventions

TypeNameDescription
DRUGMetronidazole benzoateSingle oral dose of 400 mg
DRUGFlagyl 125 mg/5 ml oral suspensionSingle oral dose of 500 mg (20 ml suspension)
DRUGFlagyl 400 mg TabletsSingle oral dose of 400 mg

Timeline

Start date
2014-06-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2014-05-23
Last updated
2014-08-01

Locations

1 site across 1 country: Jordan

Source: ClinicalTrials.gov record NCT02146209. Inclusion in this directory is not an endorsement.